Guo L, et al. - In this 16-week, prospective, randomized, open-label, multicenter, parallel-controlled study, researchers intended to confirm non-inferiority of biphasic insulin aspart 30 (BIAsp 30) + metformin to BIAsp 30 monotherapy in lowering glycated hemoglobin (HbA1c) in Chinese subjects with inadequately controlled type 2 diabetes on oral antidiabetic drugs. For this analysis, patients aged 18-79 years with HbA1c ≥ 7% were randomized to BIAsp 30 + metformin (n=130) or BIAsp 30 (n=127). It was observed that BIAsp 30 plus metformin was non-inferior to BIAsp 30 in reducing HbA1c safely.